1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Vasopharm Sees Path Forward For Traumatic Brain Injury Drug

Ronopterin Misses Primary Endpoint In NOSTRA III Trial

 
• By John Davis

Vasopharm’s ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma, suggesting a role for the compound in the condition.  

traumatic brain injury
• Source: Alamy

The NOSTRA III study of Germany’s Vasopharm GmbH’s inducible nitric oxide synthase inhibitor ronopterin (VAS203) has missed its primary endpoint in patients with traumatic brain injury (TBI), but the company believes the Phase III study has generated solid data that supports use of the compound within 12 hours of the injury, backed by a strong scientific rationale. 

Vasopharm announced the top-line results from NOSTRA III on 3 June and said it intends to discuss the findings with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

More from Therapy Areas